{"id":"W4283518065","doi":"10.1016/j.jval.2022.04.264","title":"EE12 A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab As a First-Line, 12-Month, Fixed Duration Therapy in Chronic Lymphocytic Leukemia (CLL) in Canada","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"ABB (Canada); Foothills Medical Centre","funders":"","keywords":"Obinutuzumab; Venetoclax; Medicine; Bendamustine; Fludarabine; Rituximab; Chlorambucil; Internal medicine; Ibrutinib; Population; Oncology; Chronic lymphocytic leukemia; Alemtuzumab; Cyclophosphamide; Leukemia; Chemotherapy; Lymphoma; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005887216,0.001560978,0.002994201,0.001869223,0.0009570911,0.002824092,0.002522543,0.001573542,0.007187695],"category_scores_gemma":[0.01863262,0.001242887,0.004903828,0.00320534,0.001018085,0.0009210123,0.0009831613,0.002375155,0.000274422],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.05448339,"about_ca_system_score_gemma":0.04215147,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9315313,"about_ca_topic_score_gemma":0.8869869,"domain_scores_codex":[0.99577,0.002368398,0.0001476532,0.0002955232,0.0005305025,0.0008878162],"domain_scores_gemma":[0.9892567,0.007500777,0.0006949265,0.0002715498,0.001483044,0.0007929747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.0309548,0.001171277,0.03440541,0.00176678,0.007326566,0.0003760756,0.0001431988,0.8754177,0.0005165212,0.007077563,0.01030874,0.03053539],"study_design_scores_gemma":[0.01736648,0.004479752,0.08204094,0.0008995034,0.01171827,0.0003786052,0.000593,0.8675155,0.0005485711,0.004452374,0.009703117,0.0003038227],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9144276,0.01621442,0.006786258,0.004178425,0.0001926322,0.002664213,0.03775398,0.0002924343,0.01749008],"genre_scores_gemma":[0.9847024,0.002424443,0.003020129,0.000440459,0.00004079693,0.0003074597,0.005491031,0.00003865214,0.003534607],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06846869,"threshold_uncertainty_score":0.3953065,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04631137844307062,"score_gpt":0.3219957015005659,"score_spread":0.2756843230574953,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}